Literature DB >> 28757336

Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.

Nele Van Der Steen1, Yves Mentens2, Marc Ramael3, Leticia G Leon4, Paul Germonpré5, Jose Ferri6, David R Gandara7, Elisa Giovannetti8, Godefridus J Peters9, Patrick Pauwels10, Christian Rolfo11.   

Abstract

Several oncogenic drivers have been identified in non-small cell lung cancer. Targeted therapies for these aberrations have already been successfully developed and implemented in clinical practice. Owing to improved sensitivity in genetic testing, more and more tumors with multiple driver mutations are identified, resulting in dilemmas for treating physicians whether and which targeted therapy to use. In this case series, we provide an overview of patients with intrinsic double mutations in oncogenic drivers and their reported response to targeted therapies, with a focus on epidermal growth factor receptor, anaplastic lymphoma kinase, cMET, and Kirsten rat sarcoma viral oncogene. We also include an unpublished case report on a patient with an epidermal growth factor receptor L858R and cMET exon 14 skipping.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALK; EGFR; KRAS; Non–small cell lung cancer; cMET

Mesh:

Substances:

Year:  2017        PMID: 28757336     DOI: 10.1016/j.cllc.2017.06.010

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  3 in total

1.  The rarity of concomitant genetic alterations in lung cancer.

Authors:  Laetitia Lambros; Briac Guibourg; Glen Le Flahec; Arnaud Uguen
Journal:  Mod Pathol       Date:  2018-03       Impact factor: 7.842

2.  Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma-a case report and a literature review.

Authors:  Élia Cipriano; Helena Magalhães; Catarina Tavares; João Pinto; Luís Cirnes; Fernanda Estevinho
Journal:  Porto Biomed J       Date:  2021-02-11

3.  A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients.

Authors:  Xilin Zhang; Yan Jiang; Huanming Yu; Hui Xia; Xiang Wang
Journal:  World J Surg Oncol       Date:  2020-07-16       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.